Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer
Pfizer
Pfizer
National Cancer Institute (NCI)
MedSIR
Dana-Farber Cancer Institute
Medical College of Wisconsin
Boehringer Ingelheim
Emory University
Dartmouth-Hitchcock Medical Center
Queen Mary University of London
Abramson Cancer Center at Penn Medicine
Johns Hopkins University
Palleos Healthcare GmbH
City of Hope Medical Center
Merus B.V.
Novartis
Bayer
First Affiliated Hospital, Sun Yat-Sen University
Jules Bordet Institute
National Cancer Institute (NCI)
GBG Forschungs GmbH
Masonic Cancer Center, University of Minnesota
Novartis
Spanish Breast Cancer Research Group
iOMEDICO AG
Spanish Breast Cancer Research Group
Calithera Biosciences, Inc
Shanghai Jiao Tong University School of Medicine
Japan Breast Cancer Research Group
Kyowa Kirin Co., Ltd.
Syndax Pharmaceuticals
University of Colorado, Denver
Novartis
Istituto Oncologico Veneto IRCCS
City of Hope Medical Center
NYU Langone Health
SCRI Development Innovations, LLC
University of Alabama at Birmingham
Janssen Research & Development, LLC
Merck Sharp & Dohme LLC
Ohio State University Comprehensive Cancer Center
Eli Lilly and Company
Fondazione Sandro Pitigliani
Merck Sharp & Dohme LLC
Emory University
Fudan University
Novartis
Georgetown University
Merrimack Pharmaceuticals
NYU Langone Health
Biogen